LFSC:NSD-F/m Emerald Life Sciences Innovation ETF (USD)

ETF | Others |

Last Closing

USD 20.9428

Change

-0.17 (-0.82)%

Market Cap

USD 0.05B

Volume

5.37K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
IBIT iShares Bitcoin Trust

+2.36 (+4.75%)

USD 45.40B
QQQM Invesco NASDAQ 100 ETF

+4.60 (+2.58%)

USD 39.18B
JEPQ JPMorgan Nasdaq Equity Premium..

+1.08 (+2.26%)

USD 22.49B
ACWI iShares MSCI ACWI ETF

+2.47 (+2.25%)

USD 18.95B
CGABL The Carlyle Group Inc. 4.625% ..

+0.18 (+1.09%)

USD 16.14B
SNDK Sandisk Corp

-0.19 (-0.64%)

USD 5.99B
TBIL Rbb Fund Inc - Us Treasury 3 M..

+0.01 (+0.02%)

USD 5.43B
TSLL Direxion Shares ETF Trust - Di..

+0.61 (+9.00%)

USD 4.44B
NVDL GraniteShares 1.5x Long NVDA D..

+1.18 (+4.24%)

USD 3.04B
ETHA iShares Ethereum Trust ETF

+0.97 (+8.14%)

USD 2.37B

ETFs Containing LFSC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.47% 37% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.47% 37% F 56% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.05B 58% F 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike